Investing

Pot Stocks & Stocked Pots: Nektar Therapeutics & Beef Broth

Pot Stocks & Stocked Pots: Nektar Therapeutics & Beef Broth

Nectar was the drink of the gods in Greek and Roman mythology. In another Greek myth, the god Hermes divided a sacrifice of two cows he had stolen from Apollo, on the banks of the river at Olympia and then prepared the meats as a stew and divided them into twelve portions. That’s the connection here, so feel free to invite 11 friends over for eating and investing.

Ingredients
4 pounds meaty beef soup bones (beef shanks or short ribs)
3 medium carrots, cut into chunks
3 celery ribs, cut into chunks
2 medium onions, quartered
1/2 cup warm water (110° to 115°)
3 bay leaves and 3 garlic cloves
8 to 10 whole peppercorns
3 to 4 sprigs fresh parsley
1 teaspoon dried thyme
1 teaspoon dried marjoram
Cannabis infused olive oil
1 teaspoon dried oregano
Cold water

Directions
Preheat oven to 450°. In a large roasting pan, bake soup bones, uncovered, 30 minutes. Add carrots, celery and onions. Bake 30 minutes; drain fat. Using a slotted spoon, transfer bones and vegetables to a large Dutch oven. Add warm water to roasting pan; stir to loosen browned bits. Transfer pan juices to Dutch oven. Add seasonings and enough cold water just to cover. Slowly bring to a boil, about 30 minutes. Reduce heat; simmer, uncovered, 4-5 hours, skimming foam. Add cannabis olive oil in the last 25 minutes and keep on low heat. Add water during first 2 hours to keep ingredients covered if necessary. Remove beef bones. Remove meat and discard bones; save meat for another use. Strain broth through a cheesecloth-lined colander, discarding vegetables and seasonings. If using immediately, skim fat. Or refrigerate 8 hours or overnight; remove fat from surface. This beef broth can be covered and refrigerated up to 3 days or frozen 4-6 months.

Nektar Therapeutics
Nektar Therapeutics was founded in 1990 and is based in San Francisco, California, and is a biopharmaceutical company which develops breakthrough medicinal products. They create new products by applying platform technologies to established or novel medicines. Shares of Nektar Therapeutics (NASDAQ:NKTR) fell 45% in last year, according to data from S&P Global Market Intelligence. Bristol-Myers Squibb (NYSE:BMY) handed Nektar $1.85 billion up front for rights to co-develop and co-commercialize NKTR-214. Nektar stock shot up because, on top of the huge upfront payment, Nektar remains entitled to 65% of NKTR-214 profits, and Bristol has to pay for a minimum of 67.5% of the development costs. Now, in 2019 things are starting to turn around. Nektar is traded under umbrella of the Healthcare sector, and currently shares shows upbeat performance moved up 7.23% to trade at $44.52 in the last beat. Return on investment (ROI) reached to 56.40%. Detecting profitability, the Company has a profit margin of 59.70%, gross margin of 97.90% and an operating of 61.20%. The stock price changed 9.44% in the past week. Nektar says they are in the business of “Cutting-edge chemistry and Life-changing biology.” If you’d like to learn more and possibly invest, visit them at nektar.com.

Patrick Ian Moore

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Most Popular

Interested in advertising?

Call or email us: info@edibleslist.com | 310.601.7299

Facebook

Twitter Feed

Disclaimer:

By using our website you are certifying that you are above the age of 21 years old.

Copyright © 2018 Edibles List Magazine / Edibles List, LLC

To Top